NDAINHALATIONAEROSOL, METERED
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TILADE (nedocromil sodium) is an inhaled anti-inflammatory aerosol approved in 1992 for asthma maintenance therapy. It functions as a mast cell stabilizer and works by preventing inflammatory mediator release in the airways. The drug is indicated for patients with mild-to-moderate persistent asthma requiring daily controller therapy.
LOE Approaching
As LOE approaches, TILADE teams are likely focused on cost management and transition planning rather than growth initiatives; headcount and investment are typically declining.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TILADE offers limited career upside given its LOE-approaching status and declining market relevance; roles are primarily defensive and focused on managed decline. This product is best suited for early-career professionals seeking stability or those nearing transitions within the organization.
Field SalesBrand Manager
Worked on TILADE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.